Previous 10 | Next 10 |
Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter PR Newswire Gross product sales increased 75% and Prescriptions dispensed increased 45%, over prior quarter CRANBURY, N.J. , July 26...
Palatin Technologies, Inc. (PTN) Q3 2022 Results Conference Call May 17, 2022 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantgi...
Palatin Tech press release (NYSE:PTN): Q3 GAAP EPS of -$0.03 beats by $0.01. Revenue of $0.22M (+144.4% Y/Y) misses by $1.12M. "Patient enrollment is on track for our lead programs, a Phase 3 pivotal study of PL9643 in patients with dry eye disease with topline results currently expected in t...
Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update PR Newswire Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 202...
Palatin Tech (NYSE:PTN) is scheduled to announce Q3 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.03 (-50.0% Y/Y) and the consensus Revenue Estimate is $0.35M (+288.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 ...
Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock PR Newswire CRANBURY, N.J. , May 12, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company d...
Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022 PR Newswire CRANBURY, N.J. , May 11, 2022 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fis...
Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference PR Newswire Posters highlight Palatin's ocular research and PL9643 Phase 2 clinical data CRANBURY, N.J. , May 2, 2022 /PRNewswire/ -- Pala...
Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022 PR Newswire Presentation to review the role of melanocortins in the treatment of ocular disease and Phase 2 study results with Palatin's compound PL9643 for Dry Eye Di...
Penny stocks are well known for their volatility. They’re also known for producing big wins for investors who are willing to take on high-risk trades. This week, the broader markets have gotten off to another choppy start, but that doesn’t seem to have become a concern for sma...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Sympt...
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...